End-of-day quote
Shanghai S.E.
06:00:00 2024-05-16 pm EDT
|
5-day change
|
1st Jan Change
|
6.76
CNY
|
-0.29%
|
|
-1.60%
|
-13.55%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,381
|
3,955
|
4,303
|
3,897
|
3,700
|
4,535
|
Enterprise Value (EV)
1 |
3,099
|
4,109
|
4,497
|
4,421
|
3,787
|
4,240
|
P/E ratio
|
13.1
x
|
14.8
x
|
29.7
x
|
14.1
x
|
14
x
|
15.5
x
|
Yield
|
-
|
-
|
1.62%
|
-
|
-
|
1.84%
|
Capitalization / Revenue
|
0.48
x
|
0.47
x
|
0.54
x
|
0.42
x
|
0.38
x
|
0.44
x
|
EV / Revenue
|
0.44
x
|
0.49
x
|
0.56
x
|
0.47
x
|
0.39
x
|
0.41
x
|
EV / EBITDA
|
7.79
x
|
10.1
x
|
16.7
x
|
10.3
x
|
9.29
x
|
9.85
x
|
EV / FCF
|
10
x
|
-8.81
x
|
-95.9
x
|
-28.7
x
|
9.25
x
|
11.6
x
|
FCF Yield
|
9.96%
|
-11.4%
|
-1.04%
|
-3.48%
|
10.8%
|
8.65%
|
Price to Book
|
2.14
x
|
2.14
x
|
2.16
x
|
1.77
x
|
1.5
x
|
1.65
x
|
Nbr of stocks (in thousands)
|
579,889
|
579,889
|
579,889
|
579,889
|
579,889
|
579,889
|
Reference price
2 |
5.830
|
6.820
|
7.420
|
6.720
|
6.380
|
7.820
|
Announcement Date
|
3/1/19
|
4/10/20
|
3/19/21
|
3/25/22
|
3/27/23
|
3/27/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
7,055
|
8,354
|
8,005
|
9,315
|
9,641
|
10,390
|
EBITDA
1 |
397.9
|
408.2
|
270
|
427.2
|
407.5
|
430.5
|
EBIT
1 |
369.3
|
382.3
|
245.5
|
404.9
|
387.9
|
411.7
|
Operating Margin
|
5.23%
|
4.58%
|
3.07%
|
4.35%
|
4.02%
|
3.96%
|
Earnings before Tax (EBT)
1 |
345.7
|
361.3
|
219.7
|
358.6
|
345.6
|
393.4
|
Net income
1 |
257.9
|
267.3
|
145.3
|
277.3
|
263.4
|
292.2
|
Net margin
|
3.65%
|
3.2%
|
1.81%
|
2.98%
|
2.73%
|
2.81%
|
EPS
2 |
0.4447
|
0.4600
|
0.2500
|
0.4782
|
0.4543
|
0.5038
|
Free Cash Flow
1 |
308.7
|
-466.5
|
-46.88
|
-154
|
409.5
|
366.9
|
FCF margin
|
4.38%
|
-5.58%
|
-0.59%
|
-1.65%
|
4.25%
|
3.53%
|
FCF Conversion (EBITDA)
|
77.59%
|
-
|
-
|
-
|
100.48%
|
85.21%
|
FCF Conversion (Net income)
|
119.72%
|
-
|
-
|
-
|
155.42%
|
125.57%
|
Dividend per Share
|
-
|
-
|
0.1200
|
-
|
-
|
0.1440
|
Announcement Date
|
3/1/19
|
4/10/20
|
3/19/21
|
3/25/22
|
3/27/23
|
3/27/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
154
|
194
|
524
|
86.9
|
-
|
Net Cash position
1 |
282
|
-
|
-
|
-
|
-
|
295
|
Leverage (Debt/EBITDA)
|
-
|
0.3784
x
|
0.7182
x
|
1.226
x
|
0.2132
x
|
-
|
Free Cash Flow
1 |
309
|
-467
|
-46.9
|
-154
|
409
|
367
|
ROE (net income / shareholders' equity)
|
16.2%
|
15.6%
|
7.55%
|
13.2%
|
11.3%
|
11.2%
|
ROA (Net income/ Total Assets)
|
4.99%
|
4.8%
|
2.66%
|
3.97%
|
3.51%
|
3.55%
|
Assets
1 |
5,169
|
5,571
|
5,463
|
6,982
|
7,501
|
8,224
|
Book Value Per Share
2 |
2.720
|
3.190
|
3.440
|
3.790
|
4.250
|
4.740
|
Cash Flow per Share
2 |
0.8700
|
0.6400
|
0.7200
|
1.390
|
2.040
|
2.270
|
Capex
1 |
5.73
|
8.33
|
14
|
12.2
|
6.42
|
23.5
|
Capex / Sales
|
0.08%
|
0.1%
|
0.17%
|
0.13%
|
0.07%
|
0.23%
|
Announcement Date
|
3/1/19
|
4/10/20
|
3/19/21
|
3/25/22
|
3/27/23
|
3/27/24
|
|
1st Jan change
|
Capi.
|
---|
| -13.55% | 543M | | +21.93% | 73.38B | | -1.71% | 24.13B | | +7.33% | 8.78B | | +10.34% | 8.59B | | -19.80% | 8.06B | | +14.16% | 5.26B | | -0.03% | 4.21B | | +12.70% | 4.17B | | -2.54% | 3.89B |
Pharmaceuticals Wholesale
|